Cargando…
The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study
BACKGROUND: The aim of this study was to examine the role of C-peptide as a biological marker of cardiometabolic risk in polycystic ovary syndrome (PCOS). METHODS: This case-control study enrolled 385 PCOS patients and 240 normal cycling women. Anthropometric and clinical variables were taken at fir...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798275/ https://www.ncbi.nlm.nih.gov/pubmed/29416587 http://dx.doi.org/10.14740/jocmr3325w |
_version_ | 1783297837387218944 |
---|---|
author | de Medeiros, Sebastiao Freitas Angelo, Laura Camila Antunes de Medeiros, Matheus Antonio Souto Banhara, Camila Regis Barbosa, Bruna Barcelo Yamamoto, Marcia Marly Winck |
author_facet | de Medeiros, Sebastiao Freitas Angelo, Laura Camila Antunes de Medeiros, Matheus Antonio Souto Banhara, Camila Regis Barbosa, Bruna Barcelo Yamamoto, Marcia Marly Winck |
author_sort | de Medeiros, Sebastiao Freitas |
collection | PubMed |
description | BACKGROUND: The aim of this study was to examine the role of C-peptide as a biological marker of cardiometabolic risk in polycystic ovary syndrome (PCOS). METHODS: This case-control study enrolled 385 PCOS patients and 240 normal cycling women. Anthropometric and clinical variables were taken at first visit. Fasting C-peptide, glucose, lipids, and hormone measurements were performed. Simple and multiple correlations between C-peptide and other variables associated with dysmetabolism and cardiovascular disease were examined. RESULTS: C-peptide was well correlated with several anthropometric, metabolic, and endocrine parameters. In PCOS patients, stepwise multiple regression including C-peptide as the criterion variable and other predictors of cardiovascular disease risk provided a significant model in which the fasting C-peptide/glucose ratio, glucose, body weight, and free estrogen index (FEI) were retained (adjusted R(2) = 0.988, F = 7.161, P = 0.008). CONCLUSION: C-peptide levels alone or combined with C-peptide/glucose ratio, glucose, body weight, and FEI provided a significant model to identify PCOS patients with higher risk of future cardiometabolic diseases. |
format | Online Article Text |
id | pubmed-5798275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57982752018-02-07 The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study de Medeiros, Sebastiao Freitas Angelo, Laura Camila Antunes de Medeiros, Matheus Antonio Souto Banhara, Camila Regis Barbosa, Bruna Barcelo Yamamoto, Marcia Marly Winck J Clin Med Res Original Article BACKGROUND: The aim of this study was to examine the role of C-peptide as a biological marker of cardiometabolic risk in polycystic ovary syndrome (PCOS). METHODS: This case-control study enrolled 385 PCOS patients and 240 normal cycling women. Anthropometric and clinical variables were taken at first visit. Fasting C-peptide, glucose, lipids, and hormone measurements were performed. Simple and multiple correlations between C-peptide and other variables associated with dysmetabolism and cardiovascular disease were examined. RESULTS: C-peptide was well correlated with several anthropometric, metabolic, and endocrine parameters. In PCOS patients, stepwise multiple regression including C-peptide as the criterion variable and other predictors of cardiovascular disease risk provided a significant model in which the fasting C-peptide/glucose ratio, glucose, body weight, and free estrogen index (FEI) were retained (adjusted R(2) = 0.988, F = 7.161, P = 0.008). CONCLUSION: C-peptide levels alone or combined with C-peptide/glucose ratio, glucose, body weight, and FEI provided a significant model to identify PCOS patients with higher risk of future cardiometabolic diseases. Elmer Press 2018-03 2018-01-26 /pmc/articles/PMC5798275/ /pubmed/29416587 http://dx.doi.org/10.14740/jocmr3325w Text en Copyright 2018, de Medeiros et al. http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article de Medeiros, Sebastiao Freitas Angelo, Laura Camila Antunes de Medeiros, Matheus Antonio Souto Banhara, Camila Regis Barbosa, Bruna Barcelo Yamamoto, Marcia Marly Winck The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study |
title | The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study |
title_full | The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study |
title_fullStr | The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study |
title_full_unstemmed | The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study |
title_short | The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study |
title_sort | role of c-peptide as marker of cardiometabolic risk in women with polycystic ovary syndrome: a controlled study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798275/ https://www.ncbi.nlm.nih.gov/pubmed/29416587 http://dx.doi.org/10.14740/jocmr3325w |
work_keys_str_mv | AT demedeirossebastiaofreitas theroleofcpeptideasmarkerofcardiometabolicriskinwomenwithpolycysticovarysyndromeacontrolledstudy AT angelolauracamilaantunes theroleofcpeptideasmarkerofcardiometabolicriskinwomenwithpolycysticovarysyndromeacontrolledstudy AT demedeirosmatheusantoniosouto theroleofcpeptideasmarkerofcardiometabolicriskinwomenwithpolycysticovarysyndromeacontrolledstudy AT banharacamilaregis theroleofcpeptideasmarkerofcardiometabolicriskinwomenwithpolycysticovarysyndromeacontrolledstudy AT barbosabrunabarcelo theroleofcpeptideasmarkerofcardiometabolicriskinwomenwithpolycysticovarysyndromeacontrolledstudy AT yamamotomarciamarlywinck theroleofcpeptideasmarkerofcardiometabolicriskinwomenwithpolycysticovarysyndromeacontrolledstudy AT demedeirossebastiaofreitas roleofcpeptideasmarkerofcardiometabolicriskinwomenwithpolycysticovarysyndromeacontrolledstudy AT angelolauracamilaantunes roleofcpeptideasmarkerofcardiometabolicriskinwomenwithpolycysticovarysyndromeacontrolledstudy AT demedeirosmatheusantoniosouto roleofcpeptideasmarkerofcardiometabolicriskinwomenwithpolycysticovarysyndromeacontrolledstudy AT banharacamilaregis roleofcpeptideasmarkerofcardiometabolicriskinwomenwithpolycysticovarysyndromeacontrolledstudy AT barbosabrunabarcelo roleofcpeptideasmarkerofcardiometabolicriskinwomenwithpolycysticovarysyndromeacontrolledstudy AT yamamotomarciamarlywinck roleofcpeptideasmarkerofcardiometabolicriskinwomenwithpolycysticovarysyndromeacontrolledstudy |